vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Revolve Group, Inc. (RVLV). Click either name above to swap in a different company.
Revolve Group, Inc. is the larger business by last-quarter revenue ($324.4M vs $247.1M, roughly 1.3× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 5.7%, a 5.4% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 10.4%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-13.3M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 9.5%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Revolve Theatre Company is a Henley-on-Thames based theatre company specialising in political and Shakespearean plays. The company is owned by Oliver Dench, Joe Morris and Tom Smith.
ANIP vs RVLV — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $324.4M |
| Net Profit | $27.5M | $18.6M |
| Gross Margin | — | 53.3% |
| Operating Margin | 14.1% | 6.3% |
| Net Margin | 11.1% | 5.7% |
| Revenue YoY | 29.6% | 10.4% |
| Net Profit YoY | 367.5% | 50.4% |
| EPS (diluted) | $1.14 | $0.27 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $324.4M | ||
| Q3 25 | $227.8M | $295.6M | ||
| Q2 25 | $211.4M | $309.0M | ||
| Q1 25 | $197.1M | $296.7M | ||
| Q4 24 | $190.6M | $293.7M | ||
| Q3 24 | $148.3M | $283.1M | ||
| Q2 24 | $138.0M | $282.5M | ||
| Q1 24 | $137.4M | $270.6M |
| Q4 25 | $27.5M | $18.6M | ||
| Q3 25 | $26.6M | $21.2M | ||
| Q2 25 | $8.5M | $10.2M | ||
| Q1 25 | $15.7M | $11.8M | ||
| Q4 24 | $-10.3M | $12.3M | ||
| Q3 24 | $-24.2M | $11.0M | ||
| Q2 24 | $-2.3M | $15.4M | ||
| Q1 24 | $18.2M | $10.9M |
| Q4 25 | — | 53.3% | ||
| Q3 25 | — | 54.6% | ||
| Q2 25 | — | 54.1% | ||
| Q1 25 | — | 52.0% | ||
| Q4 24 | — | 52.5% | ||
| Q3 24 | — | 51.2% | ||
| Q2 24 | — | 54.0% | ||
| Q1 24 | — | 52.3% |
| Q4 25 | 14.1% | 6.3% | ||
| Q3 25 | 15.9% | 7.1% | ||
| Q2 25 | 6.6% | 5.8% | ||
| Q1 25 | 13.3% | 5.0% | ||
| Q4 24 | -2.3% | 3.9% | ||
| Q3 24 | -13.8% | 5.0% | ||
| Q2 24 | 3.7% | 5.8% | ||
| Q1 24 | 14.8% | 3.4% |
| Q4 25 | 11.1% | 5.7% | ||
| Q3 25 | 11.7% | 7.2% | ||
| Q2 25 | 4.0% | 3.3% | ||
| Q1 25 | 8.0% | 4.0% | ||
| Q4 24 | -5.4% | 4.2% | ||
| Q3 24 | -16.3% | 3.9% | ||
| Q2 24 | -1.7% | 5.4% | ||
| Q1 24 | 13.2% | 4.0% |
| Q4 25 | $1.14 | $0.27 | ||
| Q3 25 | $1.13 | $0.29 | ||
| Q2 25 | $0.36 | $0.14 | ||
| Q1 25 | $0.69 | $0.16 | ||
| Q4 24 | $-0.45 | $0.18 | ||
| Q3 24 | $-1.27 | $0.15 | ||
| Q2 24 | $-0.14 | $0.21 | ||
| Q1 24 | $0.82 | $0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $292.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $512.5M |
| Total Assets | $1.4B | $765.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $292.3M | ||
| Q3 25 | $262.6M | $315.4M | ||
| Q2 25 | $217.8M | $310.7M | ||
| Q1 25 | $149.8M | $300.8M | ||
| Q4 24 | $144.9M | $256.6M | ||
| Q3 24 | $145.0M | $252.8M | ||
| Q2 24 | $240.1M | $244.7M | ||
| Q1 24 | $228.6M | $273.4M |
| Q4 25 | $540.7M | $512.5M | ||
| Q3 25 | $505.8M | $490.2M | ||
| Q2 25 | $436.8M | $468.6M | ||
| Q1 25 | $418.6M | $453.4M | ||
| Q4 24 | $403.7M | $437.8M | ||
| Q3 24 | $405.9M | $420.8M | ||
| Q2 24 | $455.8M | $405.8M | ||
| Q1 24 | $452.0M | $389.9M |
| Q4 25 | $1.4B | $765.0M | ||
| Q3 25 | $1.4B | $751.3M | ||
| Q2 25 | $1.3B | $722.9M | ||
| Q1 25 | $1.3B | $713.9M | ||
| Q4 24 | $1.3B | $665.5M | ||
| Q3 24 | $1.3B | $670.9M | ||
| Q2 24 | $920.8M | $657.8M | ||
| Q1 24 | $914.5M | $650.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $-10.2M |
| Free Cash FlowOCF − Capex | $29.1M | $-13.3M |
| FCF MarginFCF / Revenue | 11.8% | -4.1% |
| Capex IntensityCapex / Revenue | 0.5% | 1.0% |
| Cash ConversionOCF / Net Profit | 1.10× | -0.55× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $48.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $-10.2M | ||
| Q3 25 | $44.1M | $11.8M | ||
| Q2 25 | $75.8M | $12.6M | ||
| Q1 25 | $35.0M | $45.1M | ||
| Q4 24 | $15.9M | $3.9M | ||
| Q3 24 | $12.5M | $9.1M | ||
| Q2 24 | $17.4M | $-24.7M | ||
| Q1 24 | $18.3M | $38.4M |
| Q4 25 | $29.1M | $-13.3M | ||
| Q3 25 | $38.0M | $7.5M | ||
| Q2 25 | $71.8M | $10.4M | ||
| Q1 25 | $32.5M | $43.4M | ||
| Q4 24 | $13.5M | $2.1M | ||
| Q3 24 | $7.7M | $8.0M | ||
| Q2 24 | $13.0M | $-25.7M | ||
| Q1 24 | $13.7M | $36.7M |
| Q4 25 | 11.8% | -4.1% | ||
| Q3 25 | 16.7% | 2.5% | ||
| Q2 25 | 34.0% | 3.4% | ||
| Q1 25 | 16.5% | 14.6% | ||
| Q4 24 | 7.1% | 0.7% | ||
| Q3 24 | 5.2% | 2.8% | ||
| Q2 24 | 9.4% | -9.1% | ||
| Q1 24 | 10.0% | 13.5% |
| Q4 25 | 0.5% | 1.0% | ||
| Q3 25 | 2.7% | 1.5% | ||
| Q2 25 | 1.9% | 0.7% | ||
| Q1 25 | 1.3% | 0.6% | ||
| Q4 24 | 1.3% | 0.6% | ||
| Q3 24 | 3.2% | 0.4% | ||
| Q2 24 | 3.2% | 0.4% | ||
| Q1 24 | 3.3% | 0.6% |
| Q4 25 | 1.10× | -0.55× | ||
| Q3 25 | 1.66× | 0.56× | ||
| Q2 25 | 8.87× | 1.24× | ||
| Q1 25 | 2.23× | 3.82× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.83× | ||
| Q2 24 | — | -1.60× | ||
| Q1 24 | 1.00× | 3.53× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
RVLV
| Fashion Apparel | $155.1M | 48% |
| Dresses | $76.4M | 24% |
| Handbags Shoes And Accessories | $67.6M | 21% |
| Beauty | $20.3M | 6% |
| Manufactured Product Other | $5.0M | 2% |
| Breakage On Store Credit And Gift Cards | $900.0K | 0% |
